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Abstract 
Background: Obesity is rapidly increasing worldwide, and it results from a 
chronic imbalance between energy intake and energy expenditure. Obesity is not 
only linked to increased risk of chronic disease and life threatening comorbidities 
such as diabetes, hypertension and dyslipidemia, but has also been shown to 
increase risk of reproductive problems. The aim of this study was to determine 
the relationship between female sex hormones and obesity. 
Subjects and Methods: This was observational descriptive retrospective cross 
sectional study conducted at Dr.Alsir Fertility Center in Khartoum –Sudan. The 
study included all females attended the center between January – December 2017. 
Only 111 females satisfied the inclusion and exclusion criteria and involved in 
the study. Sociodemographic data such as age, residence and occupation were 
collected from patients' files. Anthropometric measurements were collected from 
patients' files. Participants were classified according to their body mass index into 
obese and overweight and normal. Female sex hormones levels ( prolactin, 
follicle stimulating hormone, luteinizing hormone and Anti-Müllerian  hormone)  
were obtained from laboratory records. Data were entered and analyzed using 
SPSS version 23. Independent T test was used to compare between two study 
groups. P value < 0.05 was considered significant. 
Results: The prevalence of obesity among participants was 82%. Obese and 
overweight women showed significant higher levels of Luteinizing hormone, 
follicle stimulating hormone and AMH than normal women. However, there was 
no significant difference in prolactin level between the two study groups.  
Conclusion: Infertile women had higher prevalence of overweight and obesity. 
Obesity had significant effects on female sex hormones which could explain the 
relationship between obesity and infertility. Weight reduction and physical 
exercise are recommended for obese women in reproductive age. 
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 المستخلص
زيادة الوزن والسمنة في كل العالم. تعتبر : هنالك زيادة متطردة في عدد الاشخاص المصابين ب المقدمة
السمنة احدى العوامل المؤدية للامراض المزمنة كارتفاع ضغط الدم ومرض السكري. أيضا تتسبب السمنة 
  .في مدى الخصوبة خاصة لدى النساء في عمر الانجاب
 للخصوبةولذلك هدفت هذه الدراسة الى ايجاد علاقة بين السمنة ومستوى هرمونات الانوثة بمركز د. السر 
 بالخرطوم  
تعتبر هذه الدراسة وصفية مقطعية وشملت كل النساء اللاتي ترددن على مركز الخصوبة  طرق البحث:
ولكن بعد تطبيق عوامل الاقصاء  005. عدد المترددات كان حوالي  7102في الفترة من يناير الى ديسمبر 
فقط. المعلومات الشخصية والاجتماعية مثل العمر والسكن والعمل تم استخلاصها  111والضم تم اختيار 
من الملف الخاص بكل مريضة. أيضا تم تسجيل القياسات الجسدية من ملف المريضات وتم تقسيم 
السمنة ومجموعة النساء الطبيعيات . مستوى المشاركات حسب كتلة الجسم الى مجموعة زيادة الوزن و
(هرمون الجسم الاصفرو الهرمون المحفز للحويصلات والهرمون المثبط لقتاة مولريان الهرمونات
تم استخراجها من نتائج المعمل الخاصة بكل مريضة. تم ادخال البيانات وتحليلها  وهلرمون الرضاعة)
ضا تم اجراء المقارنة في مستوى الهرمونات الانثوية بين اي .بواسطة برنامج حزم الأحصاء الاجتماعي 
  50.0مجموعتي الدراسة باستخدام اختبار تي للطلاب. مستوى العلاقة المعنوية تم اعتبارها اقل من 
% . هنالك علاقة معنوية 28نسبة الاصابة بزيادة الوزن والسمنة وسط المشاركات كانت حوالي النتائج: 
احصائيا بين مستوى الهرمونات الانثوية وكتلة الجسم . هنالك فرق معنوى احصائيا في مستوى هرموني 
مستوى . لايوجد فرق معنوي احصائيا في الجسم الاصفر والمحفز للحويصلات بين مجموعتي الدراسة 
 هرمون الضاعة بين المجموعتين. 
هنالك نسبة مرتفعة لزيادة الوزن والسمنة وسط المشاركات في البحث. هنالك اثر واضح لزيادة  الخلاصة:
الوزن والسمنة ومستوى الهرمونات الانثوية مما قد يفسر العلاقة بين زيادة الوزن والسمنة والعقم. انقاص 
ن احدى الوسائل لعلاج السمنة لدى النساء المصابات بالسمنة مما قد يقلل الوزن وممارسة الرياضة قد تكو
     .من خطر الاصابة بالعقم
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Introduction 
1.1. Background 
Obesity, which is an important health issue, is a common problem among women 
of reproductive age.  Obesity and overweight involves an abnormal and excessive 
fat accumulation that negatively affects the health of the body. According to  the  
World  Health  Organization  (WHO),  if  the  body  mass index (BMI) equals to 
or is greater than 25 kg/m2 , it is considered  overweight,  whereas  if  the  BMI  
equals  to  or  is  greater than 30 kg/m2,it is considered obesity(1). The prevalence 
of obesity is increasing significantly worldwide. The International Obesity Task 
Force reported that 1.1 billion adults are overweight. They also reported that 312 
million of them are obese (2). Approximately 3.4 million adults die each year 
because of health problems associated with obesity and being overweight.  Of 
these, 44% of  the  problems are related to diabetes, 23% to ischemic heart 
disease, and between 7% and 41% to some malignancies associated with  
overweight  and  obesity (2).  The prevalence of  obesity has  increased  in  
developed  countries  because  of  a  change in  lifestyle,  including  reduced  
physical  activity,  changes  in nutrition style, and an increased calorie intake (3). 
However, some  other  factors  such  as  endocrine  disorders,  hormonal disorders,  
psychological  disorders,  and  use  of  some  drugs such as steroids and 
antidepressants may lead to obesity (4). The World Health Organization reported 
that 60% of women are  overweight (≥25 kg/m2)  in  the  United  States  and  
most European countries and 30% of these are obese (≥30 kg/m2) and 6% of 
these are morbidly obese (≥35 kg/m2) (1–3) 
Obesity brings out  many  problems  such  as  social,  psychological,  
demographic,  and  health  problems.  It is related to increased health risks such 
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as  diabetes  mellitus,  hypertension, coronary heart disease, and osteoarthritis 
and is linked to  various  malignancies,  particularly  endometrium,  breast, and 
colon cancers(5). Obesity also plays a significant role in reproductive disorders, 
particularly in women. It is associated with anovulation, menstrual disorders,  
infertility,  difficulties in assisted reproduction, miscarriage, and adverse 
pregnancy outcomes. In obese women, gonadotropin secretion is affected 
because of  the  increased  peripheral  aromatization  of  androgens to  estrogens.  
The  insulin resistance  and  hyperinsulinemia in  obese  women  lead  to  
hyperandrogenemia   (5). 
The  sex hormone-binding  globulin  (SHBG),  growth  hormone  (GH), and  
insulin-like  growth  factor  binding  proteins  (IGFBP)  are decreased and leptin 
levels are increased. Thus, the neuroregulation  of  the  hypothalamic-pituitary-
gonadal (HPG) axis deteriorates (5). These alterations may explain impaired 
ovulatory function and so reproductive health. Because  of  lower  implantation  
and  pregnancy  rates,  higher miscarriage  rates,  and  increased  maternal  and  
fetal  complications  during  pregnancy,  obese  women  have  a  lower chance to 
give birth to a healthy newborn (6,7).  
The relationship between  obesity  and  reproductive  functions has  been  known  
for  many  years  (8,9)  and  it  is  still  being explored  (10).  The negative effects 
of obesity on reproductive consequence are well known.  However,  it  is  difficult  
to describe the mechanism of how obesity affects the reproductive  system  
because  it  is  complex  and  multifactorial.  Several mechanisms are involved in 
the relationship between fertility and obesity(11). FSH and LH were higher in 
obese women while AMH was greater among normal women. (11, 12). The 
insulin resistance and leptin levels are increased and  hyperandrogenemia  occurs  
in  obese  women.  Similarly, anovulation, changes in adipokines levels  and  the  
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HPG  axis, and steroidogenesis in obese women affect the reproductive system  
(11,12). Because  of  reduced  pregnancy  rates,  increased  miscarriage rates,  and  
increased  pregnancy  complications,  live  birth  rates decrease in obese women 
in both natural and assisted conceptions.  Obesity  may  impair  reproductive  
functions  by  affecting both  the  ovaries  and  endometrium  (12).  The  HPG  
axis  deteriorates  because  of  changes  in  hormonal  and  some substrate levels.  
The  levels  of  luteinizing  hormone (LH),  androstenedione, estrone, insulin,  
triglycerides,  and  very  low  density  lipoprotein  are  increased  and  high  density  
lipoprotein  levels are decreased in obese women. Because of these changes, the 
HPG axis deteriorates and different gynecological effects occur (5). 
Socially facing infertility can be very difficult, especially if you have not yet 
found an explanation as to why you are having troubles fathering a child. Fertility 
issues are often the result of hormonal imbalances, which cause the reproductive 
system to function abnormally. Obesity is generally an important factor in female 
infertility(5).  
1.2. Research question:  -  
What are the effects of obesity on female sex hormones?  
1.3. Hypothesis: - 
H0= Obesity does not affect female sex hormones. 
H1= Obesity affects female sex hormones.  
1. 4. Objectives 
1.4.1 General Objective 
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To determine the relationship between obesity and females sex hormones 
among female attending Dr. Elsir fertility Center 2017. 
 
1.4.2. Specific Objective 
1. To determine the prevalence of obesity among female who attended 
Dr. Elsir fertility center. 
2. To determine the level of female sex hormone among obese and non-
obese women attending Dr. Elsir fertility center 
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LITERATURE REVIEW 
2.1 Overweight and Obesity 
The  World Health Organization  (WHO ) predicts that  overweight  and 
obesity may soon  replace  more  traditional  public  health  concerns  such  as  
under  nutrition  and infectious diseases  as the most significant cause of poor 
health (13) .  This prediction has become necessary because as since 2005 the 
WHO estimated that at least 400  million  adults  (9.8%)  are  obese,  with  
higher  rates  among  women  than  men(14) .  Obesity  has  become  such  a  
serious  and  prevalent  condition constituting economic burden in the 
developed countries (15)  and is on a  gradual  ascendancy  in  the  developing  
countries.  Obesity  is  a  condition  in  which excess  body fat  has accumulated 
to an extent that health may be negatively affected (13). Obesity  is  commonly  
defined  as  a  body  mass  index  (BMI)  of 30 kg/m2  or higher (13) .  This 
definition distinguishes obesity from being pre-obese  or  overweight,  which  
is  classified  as  a  BMI  of  25 kg/m2but  less  than 30 kg/m2. Overweight  
and  obesity  is associated  with  various  diseases,  particularly cardiovascular  
diseases,  diabetes  mellitus  type  2,  obstructive  sleep  apnea,  certain types 
of cancer, and osteoarthritis (16,17). In absolute terms, obesity is an increase 
of body adipose (fat tissue) mass (13). The most common clinical methods 
used to estimate obesity are by body mass index (BMI) and in terms of its 
distribution via the waist–hip ratio (17). BMI is calculated by dividing the 
subject's mass by the square of his or her height, typically expressed in metric 
units.  Although  BMI  is  a  useful  clinical  tool  that correlates  well  with  
adiposity,  it  does  not  distinguish  between  lean  and  fat  mass unlike  more  
precise  techniques  such  as  underwater  weighing,  skinfold  thickness, 
magnetic  resonance  imaging,  dual  energy  X-ray  absorptiometry  and  
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infrared spectroscopy(18) .  The location of adipose tissue (peripheral or 
abdominal) adversely affects health.  The adipose tissues deposit either 
centrally (the mesenteric and the greater and lesser omental depots contained 
within the body cavity surrounding the internal organs) or peripherally in 
subcutaneous tissue (under the skin)(11). 
Abdominal  visceral  fat  correlates  more  strongly  with  insulin  resistance,  
metabolic and reproductive fitness than subcutaneous fat (19,20) ;  although  
the  subcutaneous  depot  is  likely  to  also  contribute  to  metabolic 
abnormalities (21) .  Waist  to  hip  ratio  (WHR)  or  waist  circumferences 
,which  is  measured  midway  between  the  lowest  rib  and  the  iliac  crest , 
provide  a reasonable  estimate  of  abdominal  fat.  In  women  a  WHR  of  
>0.8  or  a  waist circumference  ≥80cm  indicate  increased  risk  of  obesity  
associated  metabolic complications and ≥88cm indicates substantially 
increased risk (13). 
Obesity  is rapidly increasing worldwide (20) . Obesity results from a chronic 
imbalance between energy intake and energy expenditure. It is well known 
that an increase in body weight and fat tissue is associated with several 
abnormalities of sex steroid balance.  Obesity alters important homeostatic 
factors such as pancreatic secretion of insulin(18).  Hyperinsulinemia  and  
insulin  resistance  are  widely accepted  to  be  involved  in  the  underlying  
mechanisms  linking  obesity  to  multiple metabolic abnormalities and to 
alteration in steroidogenesis. Such alterations involve both androgens and 
oestrogens and the overall carrier protein, sex-hormone-binding globulin  
(SHBG) (11) .  The  net  decrease  in  SHBG  concentration observed  in  
obesity,  leads  to  alterations  in  the  availability  of  free  circulating  
androgens  and  oestrogens,  for  delivery  to  target  tissues.  In  insulin  
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resistance syndrome,  excess  insulin  is  capable  of  stimulating  
steroidogenesis,  excessive androgen production from the theca cells and 
excessive oestrogen production from the granulosa cells of the ovaries. In 
addition, by directly inhibiting SHBG synthesis, excess insulin may further 
increase the delivery of free androgens to target tissues (22) . Therefore  the  
psycho-social  consequences  of  infertility  which  includes  stress, anxiety,  
depression  and  marital  difficulties  must  be  duly  considered.  The  effective 
management of infertility will, therefore, have considerable impact on 
reproductive health in Africa (23) . 
Infertility  is  defined  as  the  inability  of  a  couple  to  conceive  after  one  
year  of regularly timed (at least 3 times a week)  unprotected inter-course 
(24) . It is estimated that 25% of couples will experience an episode of 
infertility during their reproductive life.  Primary  infertility  refers  to  couples  
or  patients  who  have  had  no previous  recognized  pregnancies.  Secondary  
infertility  encompasses  patients  who have  previously  conceived,  but  are  
currently  unable  to  conceive.  It is also termed sub-fertility(18).  Infertility 
problems often arise as a result of hormonal dysfunction of the hypothalamic-
pituitary-gonadal axis.  Measurement of peptide  and  steroid hormones in the 
serum is therefore an essential aspect in the evaluation of infertility(18).  
The  single  most  important  factor  in  determining  fertility  is  the  age  of  
the  female partner.   Fertility  declines  sharply  after  the  age  of  37  and  
therefore  fertility  is significantly halved if the female partner is 35 years or 
more (24) . 
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 2.2 Impact of Obesity on Fertility 
The distribution of body fat is clearly related to infertility. Central obesity 
measured by an increased waist :hip ratio is associated with a lower probability 
of conception (25) .  Women  with  a  waist :hip  ratio  of  less  than  0.8  have  a  
higher pregnancy  rate  than  women  with  ratios  of  more  than  0.8.  Upper  
body  fatness  has been found more often in women with polycystic ovarian 
syndrome (PCOS), as well as other endocrinological and metabolic changes, such 
as increased concentrations of free  and  total  testosterone,  androstenedione,  
oestradione,  insulin,  LDL  cholesterol, triglycerides and blood glucose. Little is 
known regarding whether android body fat distribution, independent of obesity 
or anovulation, is related to fertility (25,26) . 
Fertility processes involve a complex of factors and mechanisms of both ovarian 
and extra ovarian origin. Obesity may  interfere with many neuroendocrine  and 
ovarian functions,  thereby  reducing  both  ovulatory  and  fertility  rates  in  
otherwise  healthy women (18).  Oligo-ovulation,  anovulation  and  subfertility  
are  present  in  obese  females with a relative risk of anovulatory infertility  for 
women with a BMI >27 compared with  women  of  BMI  20-25.  Many obese 
women have normal ovulatory menstrual cycles, remain fertile and have no 
apparent hyperandrogenism. However, currently there  is  substantial  evidence  
to  support  the  relationship  between  obesity  and anovulatory  infertility (27) .  
Obesity during puberty and early adolescence has a strong association with 
infertility in the future. The mechanisms via  which  obesity  is  linked  to  
anovulation  remain  unclear,  and  most  likely  several hormonal  changes  are  
involved (11) .  In  fact,  body  fat  distribution  has been  shown  to  substantially  
affect  SHBG  concentrations.  Fat  accumulation  in  the abdominal  viscera  
(visceral  fat)  has  been  described  as  a  possible  cause  of  insulin resistance  
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and  the  resulting  metabolic  syndrome.  Female  subjects  with  central obesity 
and with higher proportion of visceral fat usually have high insulin resistance 
leading  to  lower  SHBG  concentrations  in  comparison  with  matched  subjects  
with peripheral  obesity(18) .  The net decrease in SHBG concentration observed 
in obesity, leads to alterations in the availability of free circulating androgens and 
oestrogens, for delivery to target tissues. Due to the  greater reduction of SHBG 
concentration, the  percentage  of free  testosterone  fraction  tends  to  be  higher  
in  women  with  central obesity  than  in  those  with  peripheral  obesity  leading  
to  a  state  of  “functional hyperandrogenism”.  The  pattern  of  body  fat  
distribution  can  regulate  androgen production  and  metabolism  to  a  significant  
extent.  In  fact,  women  with  central obesity have higher testosterone production 
rates than those with peripheral obesity (11) . 
Approximately  half  of  all  women  with  PCOS  are  overweight  or  obese.  
Polycystic ovarian syndrome  is  the  most  common  cause  of  anovulatory  
infertility  in  young women  and  the  history  of  weight  gain  frequently  
precedes  the  onset  of  clinical manifestations  of  the  syndrome,  suggesting  a 
pathogenetic  role  of  obesity  in  the development of PCOS and the related 
infertility. Even though the total BMI in non-obese women with PCOS is normal, 
the intra-abdominal preperitoneal and visceral fat  accumulation  may  contribute  
to  the  hormonal  dysregulation  leading  to anovulation (27). 
Obesity  adversely  affects the results of fertility therapy (28), and it is associated 
with hormonal disturbances, decreased sex hormone-binding globulin, elevated  
serum  oestradiol  and  elevated  levels  of  androgens (29). Obese  anovulatory  
women  show  higher  concentrations  of  oestrone  and/or  free oestrone  than do 
either  ovulatory obese women or women with normal weight. The fact  that  
adipose  tissue  can  act  as  a  steroid  reservoir  and  a  site  of  peripheral 
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conversion  of  androgens  to  oestrogen,  could  account  for  the  greater  
oestrogen concentrations in obese women than in women of normal weight. 
However, this does not explain the differences in circulating oestrogen 
concentrations between weights matched anovulatory and ovulatory obese 
women(30). Weight loss is not accompanied by a fall in serum oestrone 
concentrations, as one might expect with a reduction in adipose tissue. 
Mobilization of steroids from the sizeable fat tissue reservoir could be one 
explanation (31) . Oestrogen augments the release of LH and inhibits the release 
of FSH, thus leading to increased LH/FSH ratio.  The  elevated  LH  level  in  turn  
stimulates  androgen secretion  by  theca  cells  of  the  ovary,  providing  the  
precursors  for  continued oestrogen  production  in  adipose  tissue.  This vicious 
cycle results in simultaneous occurrence of hyperandrogenism and 
hyperoestrogenism(18).  Long term acyclic oestrogen exposure may lead to 
excessive endometrial growth, resulting initially in oligomenorrhoea interspersed 
with episodes of menorrhagia.  In  some  women  this ultimately  leads  to  the  
development  of  endometrial hyperplasia  or  adenocarcinoma (31).  Basal serum 
LH and FSH are normal in obesity, but nocturnal LH secretion is decreased.  
Serum FSH or serum LH might be elevated in obese women.  In  subjects  with  
gonadal  dysgenesis,  there  is  an  inverse  correlation between 24-hour integrated  
serum LH levels  and total body water to body weight a ratio that is inversely 
related to the percentage of  body fat(30). The pre-ovulatory serum FSH  rise  is  
sub-normal  in  obese  pre-pubertal  girls  than  in  girls  of  normal  weight. Data 
suggest that amenorrhoea in obesity is not due to primary ovarian failure, which 
should  be  associated  with  elevated  serum  LH  and  FSH,  but  rather  to  some 
hypothalamic-pituitary abnormality (32) .  Hyperandrogenism may be 
etiologically related to amenorrhoea in obesity. Amenorrhoeic subjects have 
elevated free androgen levels, while obese eumenorrhoeic subjects do not.  
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Therefore, hyperandrogenism is associated with the amenorrhoea of obesity.  The 
hyperandrogenism is not secondary to the  amenorrhoea,  because  
amenorrhoeicsubjects of normal weight do not have elevated free androgen levels 
(18). The  conversion of  androstenedione  to  oestrone  is  increased  in  obese  
women.  This  enhanced conversion of androgens to oestrogens may be carried 
out in the adipose tissue itself, since  fat  in  vitro  can  convert  androstenedione  
to  oestrone  and  testosterone  to oestadiol. Obese women often have menstrual 
cycles with inadequate progesterone production during the luteal phase; a change 
that may account for decreased fertility (32). 
Obesity is associated with three alterations that interfere with normal ovulation, 
and these derangements can be reversed through weight loss. These alterations 
includes; Increased  peripheral  aromatization  of  androgens  to  oestrogens;  
decreased levels of SHBG resulting in increased levels of free oestradiol and  
testosterone and increased  insulin  levels  that  can  stimulate  ovarian  stromal  
tissue  production  of androgens (33) . 
Excessive  visceral body fat is associated with insulin resistance, 
hyperinsulinaemia and high insulin-like growth factor –  I (IGF –  I) bioactivity 
as a result of a decreased concentration of insulin-  like growth factor binding 
protein  -1 (IGFBP  –  1). IGF  –  I is  a  sensitizing  factor  that  enhances  the  
ability  of  granulosa  cells  in  small  antral follicles to  respond to FSH facilitating 
the induction of LH receptors(18). In the thecal cells, both insulin and IGF-I 
stimulate ovarian androgen synthesis. Therefore, insulin and  IGFs are  important 
intra-ovarian regulators, and systemic or local disturbances may result in  
alterations of spontaneous ovulation (34).  In addition to this direct role on 
ovarian function, body fat appears to be strongly related to  the  activity  of  the  
hypothalamic-pituitary  axis.  Excessive  weight  particularly influences  the  
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concentration  of  LH,  which  is  probably  the  key  hormone  in  the relationship  
between  reproduction  and  metabolism.  Obesity  is  associated  with excessive  
LH concentrations, and it has been shown that a high concentration of LH results 
in a  lower chance of conception (34).  In  overweight women  and/or  those  with  
polycystic  ovary  syndrome  (PCOS),  an  increase  in  the number  of  fat  cells  
results  in  a  cascade  of  changes,  involving  increased  leptin  and insulin  levels 
and a preferential  increase  in  LH, but not FSH, levels. The net  effect  of these  
changes  is  to  stimulate  the  partial  development  of  follicles  that  secrete 
supranormal levels of testosterone, but which rarely ovulate (hence low 
progesterone) (35) .  The aromatizing function of adipose tissue is possibly a 
means  by  which  obesity  impairs  gonadotrophin  secretion.  As  
hyperinsulinaemia decreases  SHBG  concentrations,  obesity  is associated  with  
high  concentrations  of unbound  androgens(18).  Excessive  bioavailability  and 
aromatizing  of  androgens generates  increased  oestrone  concentrations,  which  
in  turn  triggers  a  rise  in  LH secretion.  LH  subsequently  stimulates  the  
production  of  ovarian  androgens,  thus enhancing  substrate  availability  for  
the  aromatizing  system (34). 
There are four major hormonal markers that characterize the menstrual cycle: two 
are of pituitary origin  –  LH and FSH  –  and two are of ovarian origin  – 
oestradiol and progesterone (36).  The  hypothalamic-regulating  hormones  
which orchestrate  the  activities  of  the  anterior  pituitary  are  luteinizing-
releasing  hormone (LHRH),  corticotrophin-releasing  hormone  (CRH),  growth  
hormone-releasing hormone  (GHRH),  somatostatin,  thyrotrophic  hormone-
releasing  hormone  (TRH) and prolactin inhibiting factor (PIF or dopamine). 
LH-RH is a decapeptide, which is released in a pulsatile fashion to stimulate 
release of the gonadotrophins, FSH and LH, from the anterior pituitary (37). 
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2.3 LH and FSH 
The  pituitary  gonadotrophins  FSH  and  LH  are  protein  hormones  secreted  
by  the anterior pituitary gland (38). LH and FSH are glycoproteins from the  
family  which  includes  TSH  and  human  chorionic  gonadotrophin.  These 
hormones  are  composed  of  a  two  peptide  chains,  usually α  and  a  specific  
ß  –subunit. Both are glycocylated, which  determines their bioactivity  and half-  
life (39) .  Secretion of the  gonadotrophins, FSH and LH,  is  controlled by 
luliberin. This stimulates  secretion of LH more effectively than follitropin  
secretion, the  plasma  levels  of  the  sex  hormones  (oestradiol  and  progesterone  
in  females) through positive and negative  feedback. It is also controlled by 
inhibin, a hormone produced by the Graafian follicles in  females. Luliberin also 
inhibits the release of FSH (40).  FSH and  LH are also secreted in a pulsating 
fashion in concert with the pulsating release of GnRH. The magnitude of 
secretion and the rates of  secretion  of  FSH  and/or  LH  are  determined  by  the  
levels  of  ovarian  steroid hormones and other ovarian factors. When a woman 
is in a state of relative oestrogen deficiency,  the  principal  gonadotrophin  
secreted  is  FSH.  As  the  ovary  responds  to FSH secretion with oestradiol 
production, there is a negative feedback to the pituitary gland to inhibit FSH 
secretion and facilitate LH  secretion (38) . 
LH and FSH act on the gonads to stimulate gametogenesis and hormone synthesis 
(41). 
During  the  follicular  phase,  FSH  and  LH  stimulate  oestrogen  synthesis  by  
the developing  follicle.  This  initially  feeds  back  to  the  level  of  the  
hypothalamus  and possibly to the  pituitary to inhibit FSH and LH release (39).  
FSH and LH have important actions on the ovary: the main effect of FSH is to 
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stimulate growth and  development  of  Graafian  follicles,  while  LH  acts  to  
cause  ovulation(41).  
Ovarian  steroid hormones are produced through the actions of FSH and LH. As 
the Graafian  follicle  enlarges,  increasing  amounts  of  the  oestrogen,  
oestradiol,  are produced. With the mid-cycle surge of LH, ovulation occurs and 
the Graafian follicleis  converted  into  a  corpus  luteum  from  which  mainly  
progesterone  is  secreted (37) . 
A sophisticated  system of feedback loops controls the sequence of co-ordination 
ofendocrine  events  during  the  menstrual  cycle.  The  increasing  amounts  of  
oestradiolproduced  by  the  Graafian  follicle  cause  negative  feedback  to  the  
hypothalamus, inhibiting  release of LH-RH,  and therefore also of FSH(42). As 
the levels of oestradiol continue  to  rise,  however,  a  positive  feedback  loop  
is  triggered  to  the  anterior pituitary which produces a surge in FSH and, more 
importantly, a  very large surge in LH to cause ovulation. As the  amounts of 
oestradiol and progesterone produced by the fading corpus luteum decrease, a  
production of  FSH picks up and the next cycle commences (37).  In regard to 
LH secretion, the most striking event  is  a  spectacular  and  abrupt  rise  in  
concentrations  at  the  end  of  the  follicular phase:  the  pre-ovulatory  surge.  
Mean duration of the  gonadotrophin  surge  is  48 hours. It is estimated that 
ovulation occurs about 18  hours after the LH peak, or 36 hours  after the initiation 
of the LH  surge (36) .  FSH also rises at the end of the follicular phase as part of 
the pre-ovulatory gonadotrophin surge, but this increase is  more  modest  than  
that  for  LH.  Also, FSH secretion  is  the slight but physiologically very 
significant rise in  FSH on the day(s)  preceding or on the day of menstruation. 
Peak  FSH values at this time are reached  about   24 hours after menstrual flow 
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has started: the early follicular phase FSH rises. This is the only time in the 
menstrual cycle at which the FSH: LH  ratio favours FSH (36) . 
Quantitative relationships between ovarian steroids and  FSH  release  determine  
the amounts of FSH released at the end to the menstrual cycle. Sub-normal FSH 
release or abnormal FSH:  LH ratios during the inter-menstrual period may result 
in deficient follicular growth, a delay in ovulation, and/or deficiencies in the 
secretory activity of the  corpus luteum (presumably because of decreased 
amount of tissue available for luteinization),  decreased  progesterone  secretion  
(the  inadequate  luteal  phase syndrome),  and  potential  adverse  effects  on  the  
implantation  process (36) .  Follicle-stimulating  hormone  (FSH)  is  synthesized  
in  the  adenohypophysis, and  stimulates  the  growth  and  maturation  of  ovarian  
follicles,  stimulates  estrogen secretion,  promotes  the  endometrial  changes  
characteristic  of  the  first  portion (proliferative  phase)  of  the  mammalian  
menstrual  cycle  and  stimulates spermatogenesis  in  the  male(18).  Luteinizing 
hormone  (LH)  is  also  synthesized  in  the adenohypophysis and acts with FSH 
to promote ovulation and secretion of androgens and progesterone.  It instigates 
and maintains the second portion of the mammalian estrus and menstrual cycle.  
In females it is concerned with corpus luteum formation, and in males it 
stimulates the development and functional activity of testicular leydig cells (24)  
2.4 Anti-Müllerian hormone :  
Anti-Müllerian  hormone  also  known  as  AMH  is  a protein  that  in  humans  
is  encoded  by  the  AMH  gene (43).It  inhibits  the  development  of  the  
Müllerian  ducts (paramesonephric ducts) in the male embryo (44) .  It has  
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also  been  called  Müllerian  inhibiting  factor  (MIF), Müllerian  inhibiting  
hormone  (MIH),  and  Müllerianinhibiting  substance  (MIS).  It  is  named  after  
Johannes Peter Müller(45). 
AMH  is  a  protein  hormone  structurally  related  to inhibin and activin and is 
a member of the transforming growth  factor-β  (TGF-β)  family.  It  is  a  
homodimeric glycoprotein linked by disulfide bonds and a molecular weight of 
140kDa (46) . 
In  healthy  females  AMH  is  either  just  detectable  or undetectable  in  cord  
blood  at  birth  and  then  shows  a marked  rise  by  three  months  of  age;  while  
still detectable  it  falls  until  four  years  of  age  before  rising linearly  until  
eight  years  of  age  remaining  fairly constant  from  mid-childhood  to  early  
adulthood  -  it does  not  change  significantly  during  puberty;  from  25years  
of  age  AMH  declines  to  undetectable  levels  at menopause (47) . 
AMH  is  expressed  by  granulosa  cells  of  the  ovary during  the  reproductive  
years  and  controls  the formation  of  primary  follicles  by  inhibiting  excessive 
follicular  recruitment  by  Follicular  Stimulating Hormone  (FSH).  Therefore  
it  has  a  role  in folliculogenesis  and  some  authorities  suggest  it  is  a measure 
of certain aspects of ovarian function, useful in assessing conditions such as 
polycystic ovary syndrome and premature ovarian failure(48,49) . 
In a global survey it was found that more than 30% of  women  in  the  group  
aged  25  to  44  years  are overweight (BMI 25 to 30  kg/m ,2and  20% are obese) 
(50). 
Obese women have increased incidence of conditions such  as  diabetes  mellitus,  
hypertension,  cardiovascular disease,  pancreatitis,  and  musculoskeletal  
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diseases  and also obese women are more likely to have reproductive problems 
(51) . 
Obese  women  are  known  to  be  at  higher  risk  of menstrual dysfunction and 
an  ovulation, possibly due to altered  secretion  of  pulsatile  gonadotropin  
releasing hormone  (GnRH) (52) .  Obese  women  those  having regular  
menstrual  cycles  also  found  to  have  reduced fecundity (53) .  
The term “ovarian reserve” refers to the quantity and quality of a woman’s current 
reservoir of oocytes. It  is closely  associated  with  reproductive  potential  and  
can be  used  to  determine  woman’s  reproductive  age indirectly  (54). 
In women who are undergoing assisted reproductive technology  and  are  obese  
or  overweight  has  been associated  with  a  need  for  higher  doses  of 
gonadotropins,    increased  cycle  cancellation  rates,  and fewer  oocytes  
retrieved  than  in  women  of  normal weight (55) .  Lower  rates  of  pregnancy  
and  live  birth have  also  been  reported  in  these  women  with  higher 
miscarriage rates (55,56).  However, other studies have not found any negative 
effect of obesity on assisted reproductive technology (ART) out-come (57,58). 
Various  tests  have  been  performed  over  the  last twenty  years  for  assessing  
ovarian  reserve  and  to determine  follicle  number  and  quality  and  also  to 
predict the outcome of assisted reproduction procedures (45). 
The  earliest  and  most  useful  parameters  used  for evaluation of ovarian reserve 
include  woman’s age and assays of serum FSH in the  early  follicular phase 
(59,60)For  evaluation  of  ovarian  reserve,  including ovarian volume  various 
ultra-sound parameters are also used (61,62)  and the antral follicle  count, with  
varying degrees of reliability (63,64) . 
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Recently,  serum antimüllerian  hormone  levels  have been introduced as a novel 
measure of ovarian reserve(65).  
La Marca  et al (2006).  showed that serum AMH levels, unlike other ovarian 
reserve tests, do not change  significantly throughout the menstrual cycle (65).  
Other studies have also  confirmed  that  the  intercycle  and  intracycle variability 
of serum AMH levels is very low enough, to allow random timing of AMH 
measurement during the menstrual  cycle.  Hence,  it  has  been  suggested  that  
serum  AMH  values  are  more  convenient  and  more effective  than  other  
serum  ovarian  reserve  tests  like FSH and inhibin B or estradiol (66). 
AMH is a product of the granulosa cells in preantraland  antral  follicles (67) .  
Serum  AMH  levels  decline with  age  and  are  correlated  with  the  number  
of antralfollicles  and  the  ovarian  response  to hyperstimulation (68,69) .  Few 
studies have evaluated the effect of obesity on ovarian hormones.  Some  studies 
have  identified  lower  serum  AMH  levels  in obese women than in non-
obesewomen
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3.1. Study Design 
This was observational descriptive retrospective cross -section study. 
3.2. Study area 
The study was conducted at Dr. Elsir fertility Center which is located in 
Khartoum state, Khartoum2 -61 Africa street near the Indian embassy. The Dr. 
Elsir fertility Center has a pharmacy (containing drugs used to treat infertility) 
and laboratory for the all recent investigations. 
3.3. Study population 
All females who attended the Dr. Elsir fertility center during the period from 
January2016-December2017 (500). 
3.4. Inclusion and exclusion criteria: 
Any participant with known endocrine disorder such as cushing syndrome, hyper 
or hypothyroidism or reproductive diseases such as blockage of fallopian tube, 
polycystic ovary, abnormal endometrium and ovarian cyst were excluded from 
the study. Also, any woman with incomplete data or laboratory results was 
excluded. 
3.5. Sample selection: 
All patients satisfied the inclusion and exclusion criteria were included in the 
study (111) 
3.6. Data Collection Tools 
Data were collected from patient’s files. This data included sociodemographic 
data and laboratory results. 
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3.7. Variables 
*Age 
*Residence 
*Occupation  
*Level of education  
*Duration of marriage  
*Weight  
*Height  
*BMI  
* Female Sex hormone (FSH – LH –PRL–AMH) 
*Number of assisted ovulation trials. 
3.8. Data Analysis 
Data were fed in computer and analyzed using SPSS program 23. Descriptive 
data were presented as mean +/- SD. The relationship between BMI and female 
sex hormones (FSH – LH –PRL- AMH) was analyzed by Pearson correlation. 
Independent T test was used to compare between two study groups (normal and 
overweight and obese). P < 0.05 was considered significant. 
3.9. Ethical consideration 
The research was conducted after the approval of the Ethical committee at 
International University of Africa and the approval of Doctor AL sir Abo AL 
Hassan infertility center. Also, verbal consent was obtained from each 
participant. 
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Table 4.1: Age among study participants (n=111). 
 
 Mean Median Std. Deviation Minimum Maximum Std. Error 
 Age (year) 31.21 31.00 5.84 18.00 47.00 0.55 
 
The above table shows that the mean Age was (31.21years ±5.84). The minimum 
was 18 years while the maximum was 47years. 
Figure 4.1: Distribution of study participants according to their residence 
(n=111). 
 
 
 
The Figure above shows that about two thirds of participants (69.40%) were from 
inside Khartoum and about 30.60% were from outside Khartoum. 
 
  
69.40%
30.60%
Residence
Inside Khartoum Outside Khartoum
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Table 4.2: Occupation of study participants (n=111). 
 
 
Occupation Frequency Percentage 
Accountant 4 3.6% 
Doctor 4 3.6% 
Tailor 1 0.9% 
Employee 5 4.5% 
Engineer 2 1.8% 
Housewife 84 75.7% 
Student 3 2.7% 
Teacher 7 6.3% 
Lab Technician 1 0.9% 
Total 111 100.0 
 
The table above shows that most of study participants 84 (75. 7%) were 
housewives, 4 (3.65%) were accountants, 4 (3.6%) were doctors, 1 (0.9%) 
tailors, 5 (4.5%) employees, 2 (1.8 %) engineers, 3 (2.7%) students, 7 (6.3%) 
teachers, and 1 (0.9%) were lab technicians. 
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Table 4.3: Anthropometric measurements of study participants (n=111). 
 
 
  
 
 
 
The above table shows that the mean height was 161.39±8.43 cm, the mean 
weight was 79.78 ±18.76 kg and the mean BMI was 31.71 ±17.72. 
 Mean  Std. Deviation 
Height (Cm) 
161.39  8.43 
Weight (Kg) 
79.78  18.76 
BMI (Kg\m2) 
31.71  17.72 
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Figure 4.2: Prevalence of Obesity among participants (n=111). 
 
 
 
 
 
The above figure shows that about (82%) of study participants were 
overweight and obese while (18%) of study participants were normal. 
 
 
 
 
 
 
 
 
 
 
  
18%
82%
Obesity
Normal Overweight and obese
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Table4.4: Female sex hormone levels of study participant (n=111) 
   
 
 
 
 
 
The above table shows that the mean FSH level was10.54 ±16.07 mIU/L.  
The mean LH was 8.59 ±8.74 mlIU/L.The mean PRLwas114.16 ±688.01 
mlIU/L. The mean AMH was 7.82 ±8.89 mlIU/L. 
  
Hormones Mean Std. Deviation 
FSH (mIU/L) 
10.53 16.07 
LH (mIU/L) 
8.59 8.74 
PRL   ( ng/ml) 
114.16 688.01 
AMH   (ng/ml) 
7.82 8.89 
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Table 4.5 Comparison of hormones levels between overweight and obese 
women and normal women: 
 Mean Std. Deviation P value 
FSH Overweight and obese 14.94 31.58 
0.01 
Normal 9.78 10.63 
LH Overweight and obese 13.34 13.99 
0.01 
Normal 7.65 7.04 
PROL Overweight and obese 85.32 151.96 
0.61 
Normal 122.77 765.83 
AMH Overweight and obese 12.40 13.09 
0.00 
Normal 6.79 7.56 
 
 
Independent student (T) test shows significant differences in FSH, LH and 
AMH levels between normal and obese (P value = 0.01, 0.01and 0.00 
respectively). FSH and LH were higher in obese women while AMH was 
greater among normal women However, there no significant difference in PRL 
level between them (P value= 0.61)  (Table 4.7). 
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Discussion  
 
Obesity is rapidly increasing worldwide (70), and it results from a chronic 
imbalance between energy intake and energy expenditure. Excess weight is not 
only linked to increased risk of chronic disease and life threatening comorbidities 
such as diabetes, hypertension and dyslipidemia (71), but has also been shown to 
increase risk of reproductive problems (72). In this study, the prevalence of 
overweight and obesity among the infertile women was 82%. Several studies 
have shown that women with excess body weight are more likely to have fertility 
problems (53,73). It has been found that the risk of infertility is threefold higher 
in obese women than in non-obese women(74). 
The fertility of obese women is lower compared to that of women with normal 
weight, and ovulation disorders are more frequent in them (75). Pregnancy is less 
likely if the woman is obese (34). This high prevalence of obesity among infertile 
women, observed in this study. could be due to effect of obesity on female 
ovaries.  
Indeed, the present study showed that obese women had higher levels of serum 
FSH and LH than normal women. Other studies showed normal level of  
basal serum LH and FSH  in obese women(76,77) but nocturnal LH secretion has 
been decreased(78). In contrast, recent preliminary reports have suggested that  
serum LH(79) might be elevated in obese women. In subjects with gonadal 
dysgenesis, there is an inverse correlation between 24-hr integrated serum LH 
levels and the percentage of body fat,(80) and in normal subjects, serum LH 
correlates directly with the ratio of total body water to body weight(81) a ratio 
that is inversely related to the percentage of body fat. 
Mechanism leading to hyperandrogenemia is hyperinsulinemia via insulin-like 
growth factor-1 (IGF-1). IGF-1 is secreted by human ovarian tissue, and its 
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receptors are located in the ovary. Insulin can bind IGF-1 receptors as well as its 
own receptor. Insulin also decreases the production of the IGFBP-1 in liver and 
makes IGF-1 more effective. Androgen production increases from theca 
interstitial and stromal cells by the action of IGF-1(82). Insulin decreases SHBG 
production from the liver; as a result, serum androgen levels increase in obese 
women(83). 
A significant finding of the present study is that obese women had high level of 
FSH compered to non-obese women.  It is agreement by other study(84). The 
present study showed that no statistically significant difference in the prolactin 
levels between normal and obese women. This is in consistent with a study on 
women in Ludhiana(86).Same results were showed by other study(87)  . 
However, our findings are in contrast to a recent study in Bangladeshi women 
where prevalence of hyperprolactinemia was stated to be higher in infertility 
.(88). 
In a recent study in general population no correlation was observed between 
serum prolactin and obesity (89). Conversely, another study reported higher basal 
levels of prolactin in obese individuals(90).  
It has been suggested that hyperprolactinemia interferes with the action of the 
gonadotrophin at the ovarian level and results in impaired gonadal steroid 
secretion, which in turn alters positive feedback effects at the hypothalamic and 
pituitary levels. This leads to lack of gonadotrophincyclicity and to infertility(91). 
Also, prolactin can inhibit the follicular estradiol production resulting in 
infertility(92).  
Our study showed that obese women have higher levels of Serum AMH than 
normal women. There have been numerous studies examining the effect of body 
mass index on ovarian reserve via AMH levels; however, the results have been 
conflicting.  
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Shaw et al. (2011) examined 135 Caucasian premenopausal women, 16 % of 
them were obese (BMI≥30), who were younger than age 45 with a mean age of 
41±2.48 years in a prospective case-control study for the association of AMH 
levels and breast cancer risk and found no correlation between AMH levels and 
BMI (93). Sahmay et al (2012). also demonstrated no correlation between AMH 
levels and BMI during a cross-sectional study of 259 premenopausal women, 14 
% of them were obese and under the age of 45 (94). Lastly, Halawaty et al. (2010) 
reported no correlation between AMH levels and BMI in a cross-sectional 
comparative study involving 5 non-obese women whom mean age was 46.1 years 
versus 50 obese women whom mean age was 46.2 years (95).  
This was in agreement with Sahmay et al (2012) (94)and Elderet al (2005) (96) 
who showed no significant correlations between BMI and AMH levels (p>0.05). 
This finding was in contrast with the studies conducted by Skalba et al (2011) 
(97) and Buyuk et al(2011)  (98) who showed significant negative correlation 
between AMH and  BMI . According to their study, elevated BMI was associated 
with decreased serum AMH levels in infertile females with diminished ovarian 
reserve compared to ones with normal ovarian reserve(97,98).  
The mechanisms by which obesity affect ovarian function and in particular AMH 
levels remain largely unclear. Obesity may indirectly affect AMH levels through 
its potential disruption of the ovarian follicular environment. Studies have shown 
that various biochemical markers involved in both inflammatory and oxidative 
stress responses have been elevated in the follicular fluid of obese women 
compared to their non-obese counterparts (99,100). 
In conclusion, findings of the present study suggest that there is a positive 
association between obesity and various hormonal derangements which can 
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contribute to infertility. Hence management of the obese patient with infertility 
should start with a goal of achieving a significant weight loss. Intervention 
undertaken for control of central and visceral obesity would definitely provide a 
beneficial effect by correcting the hormonal imbalance. Perhaps, weight loss 
regularizes menstrual cycles and increases the chance of spontaneous ovulation 
and conception in an ovulatory overweight and obese women. 
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6.1 Limitation 
1. Sample sizes were calculated as 125 infertilities but only 111 women 
satisfied the inclusion and exclusion criteria. 
2. We used secondary data because social behavior of Sudanese female will 
not accept such research. 
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6.2 Conclusions 
 
1. The prevalence of obesity was higher in obese women compared to non-
obese women 
2. Overweight and obese women have higher FSH, AMH and LH than 
normal women. 
3. There no significant different in prolactin level between obese and 
normal women. 
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6.3 Recommendations: 
 
1. Large scale studies are needed to confirm the relationship between 
obesity and sex hormone among Sudanese infertile women.  
2. Clinical trial studies are recommended to reduce the weight of obese 
infertile women and observe it’s the effect on sex hormone parameters 
and female infertility. 
3. Experimental studies are needed to explore the mechanisms by which 
obesity affect female sex hormone level and hence causing infertility.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
References 
1.  Organization WH. Preventing and managing the global 
epidemic. Report of the World Health Organization on obesity. 
Geneva: World Health Organization; 1997.  
2.  Calhoun KC. Obesity and infertility. Obes Dur Pregnancy Clin 
Pract. 2014;3(April):11–31.  
3.  Fedorcsa´ck P, Storeng R, Dale PO, Tanbo T AT. Obesity is 
associated with early pregnancy loss after IVF or ICSI. 
ActaObstetGynecolScand. 2000;79(8):43.  
4.  Raatikainen K, Heiskanen N, Heinonen S. Transition from 
overweight to obesity worsens pregnancy outcome in a BMI-
dependent manner. Obesity (Silver Spring). 2006;14(1):165–71.  
5.  Volume M. The prevalence and impact of overweight and 
obesity in an Australian obstetric population. Med J Aust. 
2006;184(2):25–729.  
6.  Moore CA, Watkins ML, Rasmussen SA, Honein MA, Botto 
LD. Maternal Obesity and Risk for Birth Defects. Pediatr Blvd. 
2003;111(5).  
7.  Pratt LA, Brody DJ. Depression and obesity in the U.S. Adult 
household population, 2005-2010. NCHS Data Brief. 
2014;(167):1–8.  
8.  Josrph Rogers and GeorgeW. Metchell J. The Relation Of 
Obesity to Menstrual Disturbances. New England J MED; 1952. 
p. 53.  
9.  Hartz AJ, Barboriak PN, Wong A, Katayama KP RA. . The 
association of obesity with infertility and related menstrual 
abnormalities in women. Int J ObesRelMetab Dis. 1979;3:57–77.  
10.  Jungheim ES, Travieso JL, Carson KR, Moley KH. Obesity and 
Reproductive Function. Obstet Gynecol Clin North Am. 
 39 
 
2012;39(4):479–93.  
11.  Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. 
Obesity and reproductive disorders in women. Hum Reprod 
Update. 2003;9(4):359–72.  
12.  Bellver J, Melo MAB, Bosch E, Serra V, Remohí J, Pellicer A. 
Obesity and poor reproductive outcome: the potential role of the 
endometrium. Fertil Steril. 2007;88(2):446–51.  
13.  JC. S. The impact of obesity on health status: some implications 
for health care costs.  Int J ObesRelatMetabDisord. 
1995;19(Supplement 6):S13-6.  
14.  WHO. Obesity: preventing and managing the global epidemic. 
Report of a WHO consultation. WHO Technical Report Series 
894. Geneva: WHO; 2000.  
15.  Kopelman PG. Obesity as a medical problem. Nature. 
2000;404(6778):635–43.  
16.  Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, 
Kotani K, KamedaTakemuara K, Tokunaga K MY. Insulin 
resistance and body fat distribution. Diabetes Care. 
1996;19(287):91.  
17.  Björntorp P. Metabolic implications of body fat distribution. 
Diabetes Care. 1991;14(12):1132–43.  
18.  Ofori N, Akwasi P. THE CORELLATION BETWEEN 
ANTHROPOMETRY AND INFERTILITY IN WOMEN A 
THESIS SUBMITTED IN FULFILLMENT OF THE 
REQUIREMENT FOR THE DEGREE Department of 
Molecular Medicine , School of Medical Sciences College of 
Health Sciences By. 2011;  
19.  Folsom A, Kaye S, Sellers T. Body fat distribution and 5-year 
risk of death in older women. J Am Med Assoc. 1993;269:483–
7.  
 40 
 
20.  Zaadstra BM, Seidell JC, Van Noord PA, te Velde ER, Habbema 
JD, Vrieswijk B, et al. Fat and female fecundity: prospective 
study of effect of body fat distribution on conception rates. Bmj. 
1993;306(6876):484–7.  
21.  HAROLD E. LEBOVITZ M, MARY ANN BANERJI, MD F. 
Visceral Adiposity Is Causally Related to Insulin Resistance. 
Diabetes Care. 2005;28(9):2322–5.  
22.  Monga M, Alexandrescu B, Katz SE, Stein M, Ganiats T. Impact 
of infertility on quality of life, marital adjustment, and sexual 
function. Urology. 2004;63(1):126–30.  
23.  Dyer SJ, Abrahams N, Hoffman M, van der Spuy ZM. Infertility 
in South Africa: women’s reproductive health knowledge and 
treatment-seeking behaviour for involuntary childlessness. Hum 
Reprod. 2002;17(6):1657–62.  
24.  Tietz. Textbook of Clinical Chemistry and Molecular 
Diagnostics. 4th ed. Elsevier Saunders Publishers; 2006. 2021-
2027 p.  
25.  Wass P, Waldenström U, Rössner S, Hellberg D. An android 
body fat distribution in females impairs the pregnancy rate of in-
vitro fertilization-embryo transfer. Hum Reprod. 
1997;12(9):2057–60.  
26.  Crosignani PG, Vegetti W, Colombo M, Ragni G. Resumption 
of fertility with diet in overweight women. Reprod Biomed 
Online. Reproductive Healthcare Ltd, Duck End Farm, Dry 
Drayton, Cambridge CB23 8DB, UK; 2002;5(1):60–4.  
27.  Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle 
modification in polycystic ovary syndrome. Trends Endocrinol 
Metab. 2002;13(6):251–7.  
28.  Maelli, E.M. and Grazi RV. Metformin and BMI? ? Fertil Steril. 
2002;78(5):890.  
 41 
 
29.  Chong, A.P., Rafael, R.W. and Forte CC. Influence of weight in 
the induction of ovulation with human menopausal gonadotropin 
and human chorionic gonadotropin. Fertil Steril. 
1986;48(6):905–13.  
30.  Zaria IN. PATTERN OF REPRODUCTIVE HORMONES IN 
WOMEN WITH INFERTILITY BY PATTERN OF 
REPRODUCTIVE HORMONES IN WOMEN WITH 
INFERTILITY IN ZARIA , NORTHERN NIGERIA BY. 2009;  
31.  Wallach EE, Reid RL, Van Vugt DA. Weight-related changes in 
reproductive function. Fertil Steril. 1987;48(6):905–13.  
32.  Glass A, Burman K, Dahms W, Boehm T. Endocrine function in 
human obesity. Metabolism. 1981;30(1):89–104.  
33.  Speroff, L., Glass, R. H. andKase NG. Clinical Gynaecologic 
Endocrinology & Infertility. 3rd ed. . Baltimore: Williams & 
Wilkins; 1999.  
34.  Galtier-Dereure F, Pujol P, Dewailly D, Bringer J. Choice of 
stimulation in polycystic ovarian syndrome: the influence of 
obesity. Hum Reprod. 1997;12 Suppl 1:88–96.  
35.  S SR and F. Environment, lifestyle and infertility an 
intergenerational issue. Nat Cell Biol. 2002;4(supplement 
1):s33-40.  
36.  Ferin, M., Jewelewicz, R. and Warren M. The menstrual cycle: 
physiology, reproductive disorders and infertility. New York: 
Oxford University Press.; 1993.  
37.  / Willocks, J. and Neilson J. Obstetrics and Gynaecology. 4th ed. 
Edinburgh: Churchill Livingstone; 1991.  
38.  Beckmann, C.R.B., Ling, F.W., Barzansky, B.M., Bates, G.W., 
Herbert, W.N.P., Laube, D. W. and Smith RP. Obstetrics and 
Gynaecology. 2nd ed. Baltimore: Williams& Wilkins; 1995.  
 42 
 
39.  Beckmann, C.R.B., Ling, F.W., Barzansky, B.M., Bates, G.W., 
Herbert, W.N.P., Laube, D. W. and Smith R. Basic science in 
obstetrics and gynaecology. 3rd ed. Baltimore: Williams& 
Wilkins; 1995.  
40.  Meyer, B. J., Meij, H. S. and Meyer AC. Human Physiology. 
2nd ed. Cape Town: : Juta& Co, LTD; 1997.  
41.  De Swiet, M., Chamberlain, G. and Bennet P. . Basic science in 
obstetrics and gynaecology. 3rd ed. Edinburgh: Churchill 
Livingstone.; 2002.  
42.  Willocks, J. and Neilson JP. Obstetrics and Gynaecology. 4th ed. 
Edinburgh: Churchill Livingstone; 1991.  
43.  Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, 
Cheung A, et al. Isolation of the bovine and human genes for 
müllerian inhibiting substance and expression of the human gene 
in animal cells. Cell. 1986;45(5):685–98.  
44.  Visser JA, de Jong FH, Laven JSE, Themmen APN. Anti-
Mullerian hormone: a new marker for ovarian function. 
Reproduction. 2006;131(1):1–9.  
45.  Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A 
systematic review of tests predicting ovarian reserve and IVF 
outcome. Hum Reprod Update. 2006;12(6):685–718.  
46.  Prentice AM. The emerging epidemic of obesity in developing 
countries. Int J Epidemiol. 2006;35(1):93–9.  
47.  Clark  a. M, Thornley B, Tomlinson L, Galletley C, Norman RJ. 
Weight loss in obese infertile women results in improvement in 
reproductive outcome for all forms of fertility treatment. Hum 
Reprod. 1998;13(6):1502–5.  
48.  Behringer RR. of Mullerian-In hi biting Substance. Curr Top 
Deueloprnenral Biol. 1994;29:171–87.  
 43 
 
49.  Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace 
WHB. A validated model of serum Anti-Müllerian hormone 
from conception to menopause. PLoS One. 2011;6(7):1–7.  
50.  Weenen C, Laven JSE, von Bergh ARM, Cranfield M, Groome 
NP, Visser JA, et al. Anti-M??llerian hormone expression 
pattern in the human ovary: Potential implications for initial and 
cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77–83.  
51.  Broer SL, Eijkemans MJC, Scheffer GJ, Van Rooij IAJ, De Vet 
A, Themmen APN, et al. Anti-Müllerian hormone predicts 
menopause: A long-term follow-up study in normoovulatory 
women. J Clin Endocrinol Metab. 2011;96(8):2532–9.  
52.  Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang 
X, et al. Weight loss results in significant improvement in 
pregnancy and ovulation rates in anovulatory obese women. 
Hum Reprod. 1995;10(10):2705–12.  
53.  Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and 
time to pregnancy. Hum Reprod. 2007;22(2):414–20.  
54.  Gupta S, Sharma D, Surti N, Kesavan S, Khanna P, Agarwal A. 
Ovarian reserve testing: systematic review of the literature. Arch 
Med Sci. 2009;5(1A):S143–50.  
55.  Fedorcsák P, Dale PO, Storeng R, Ertzeid G, Bjercke S, Oldereid 
N, et al. Impact of overweight and underweight on assisted 
reproduction treatment. Hum Reprod. 2004;19(11):2523–8.  
56.  J X Wang, M Davies RJN. Body mass and probability of 
preganancy during assisted reproduction treatment: retrospective 
study. Bmj. 2000;321(November):1320–1.  
57.  Dechaud H, Anahory T, Reyftmann L, Loup V, Hamamah S, 
Hedon B. Obesity does not adversely affect results in patients 
who are undergoing in vitro fertilization and embryo transfer. 
Eur J Obstet Gynecol Reprod Biol. 2006;127(1):88–93.  
 44 
 
58.  Martinuzzi K, Ryan S, Luna M, Copperman AB. Elevated body 
mass index (BMI) does not adversely affect in vitro fertilization 
outcome in young women. J Assist Reprod Genet. 
2008;25(5):169–75.  
59.  JP, Philput CB, Jones JS MS. Basal follicle-stimulating hormone 
level is a better predictor of in vitro fertilization performance 
than age. Fertil Steril. 1991;55(4):784–791.  
60.  Tan SL, Royston P, Campbell S, Jacobs HS, Betts J MB. 
Cumulative conception and live birth rates after in vitro 
fertilization. Lancet;1992; 339(8806):1390–139.  
61.  Syrop CH, Willhoite A, Van Voorhis BJ. Ovarian volume: A 
novel outcome predictor for assisted reproduction. Fertil Steril. 
Elsevier Masson SAS; 1995;64(6):1167–71.  
62.  Lass A, Skull J, McVeigh E, Margara R, Winston RML. 
Measurement of ovarian volume by transvaginal sonography 
before ovulation induction with human menopausal 
gonadotrophin for in-vitro fertilization can predict poor 
response. Hum Reprod. 1997;12(2):294–7.  
63.  Laszlo F, Bancsi LF, Broekmans FJM, Eijkemans MJC, De Jong 
FH, Habbema JD, et al. Predictors of poor ovarian response in in 
vitro fertilization: A prospective study comparing basal markers 
of ovarian reserve. Fertil Steril. 2002;77(2):328–36.  
64.  Nahum R, Shifren JL, Chang Y, Leykin L, Isaacson K, Toth TL. 
Antral follicle assessment as a tool for predicting outcome in 
IVF--is it a better predictor than age and FSH? J Assist Reprod 
Genet. 2001;18(3):151–5.  
65.  La Marca A, Stabile G, Carducci Artenisio A, Volpe A. Serum 
anti-Mullerian hormone throughout the human menstrual cycle. 
Hum Reprod. 2006;21(12):3103–7.  
66.  Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, 
 45 
 
Tizard R, et al. Insensitivity to anti-müllerian hormone due to a 
mutation in the human anti-müllerian hormone receptor. Nat 
Genet. 1995;11(4):382–8.  
67.  Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian 
function: the role of anti-Mullerian hormone. Reproduction. 
2002;124(5):601–9.  
68.  Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden 
RM. Early follicular serum m??llerian-inhibiting substance 
levels are associated with ovarian response during assisted 
reproductive technology cycles. Fertil Steril. 2002;77(3):468–71.  
69.  Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LCL, 
Strauss JF. Association of anti-mullerian hormone levels with 
obesity in late reproductive-age women. Fertil Steril. 
2007;87(1):101–6.  
70.  Ogden CL. Prevalence of Overweight and Obesity in the United 
States, 1999-2004. JAMMA. 2006;295(13):1999–2004.  
71.  Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in 
incidence of diabetes, hypertension and lipid disturbances after 
intentional weight loss induced by bariatric surgery: the SOS 
Intervention Study. Obes Res. 1999;7:477–84.  
72.  Ozcan Dag Z, Dilbaz B. Impact of obesity on infertility in 
women. J Turkish Ger Gynecol Assoc [Internet]. 
2015;16(2):111–7. Available from: 
http://cms.galenos.com.tr/FileIssue/27/1078/article/111-7.pdf 
73.  Pasquali R. Obesity and infertility. Curr Opin Endocrinol 
Diabetes Obes. 2007;14(6):482–7.  
74.  Rich-Edwards JW, Goldman MB, Willet WC, Hunter DJ S, MJ, 
Colditz GA  et al. Adolescent body mass index and infertility 
caused by ovulation disorders.  Am J Obs Gynecol. 1994;171(7).  
75.  Wittemer C, Ohl J, Bailly M B-LK and NI. Does body mass 
 46 
 
index of infertile women have an impact on IVF procedure and 
outcome? ? J Assist Reprod Genet. 2000;17:547–552.  
76.  Dignam WJ, Parlow AF DT. Serum FSH and LH measurements 
in the evaluation of menstrual disorders. Am J Obs Gynecol. 
1969;105(5):679–95.  
77.  Kopelman PG, Pilkington TRE, White N  et al. Abnormal sex 
steroid secretion and binding in massively obese women. Clin 
Endocrinol. 12(4):363–9.  
78.  Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray 
CS, et al. Differences in clinical and endocrine features between 
obese and non‐ obese subjects with polycystic ovary syndrome: 
an analysis of 263 consecutive cases. clin endocinolgy. 
1990;32(2):213–20.  
79.  Plymate SR, Matej LA, Garrison MJ  et al. Regulation of sex 
steroid binding globulin by obesity. Clin Res. 1980;28:265A.  
80.  Boyar R, Ramsey J, Chipman J  et al. The regulation of 
gonadotropin secretion in gonadal dysgenesis. Clin Res. 
1978;26:490A.  
81.  Penny R, Goldstein IP FS. Correlation of luteinizing hormone 
(LH) and follicle stimulating hormone (FSH) with total body 
water (TBW) and body fat (BF). Pediatr Res. 1976;10:342.  
82.  LC. G. Insulin-like growth factors and ovarian follicular 
development. Endocr Rev. 1992;13(4):641.  
83.  Diamanti-Kandarakis E, Dunaif A. New perspectives in 
polycystic ovary syndrome. Trends Endocrinol Metab. 
1996;7(8):267–71.  
84.  Seth B, Arora S, Singh R. Association of Obesity with Hormonal 
Imbalance in Infertility : A Cross-Sectional Study in North 
Indian Women. Ind J Clin Biochem. 2013;28(4):342–7.  
 47 
 
85.  De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro 
G, Giorgino R. Inhibitory effect of obesity on gonadotropin, 
estradiol, and inhibin B levels in fertile women. Obesity. 
2006;14(11):1954–60.  
86.  Avasthi K, Kaur J, Gupta S NP. Hyperprolactinema and its 
correlation with hypothyroidism in infertile women. J Obs 
Gynaecol India. 2006;56(1):68–77.  
87.  Manuscript NPAA, Doi:10.1016/j.maturitas.2011.10.010. . 
Author manuscript; available in PMC 2013 January 01. 
Published in final edited form as: Maturitas Maturitas . 2012 
January ; 71(1): 55–61., States R of obesity-related disturbances 
with L ratio among post-menopausal women in the U, Hind 
Beydoun, PhDa, May Beydoun, PhDb, Natasha Wiggins, MPHc  
and LS, MD-PhDd. Relationship of obesity-related disturbances 
with LH/FSH ratio among post-menopausal women in the 
United States. Matur Author Manuscr. 2013;71(1):55–61.  
88.  Akhter N HS. SA. Sub-clinical hypothyroidism and 
hyperprolactinemia in infertile women: Bangladesh perspective 
after universal salt iodination. Internet J Endocrinol. 2009;5(1).  
89.  Ernst B, Thurnheer M, Schultes B. Basal serum prolactin levels 
in obesity-unrelated to parameters of the metabolic syndrome 
and unchanged after massive weight loss. Obes Surg. 
2009;19(8):1159–62.  
90.  Grimaldi F, Mazzolini A, Paterniti BR, Torossi I, Proto G BF. 
Changes in secretion of prolactin in obesity. Minerva 
Endocrinol. 1990;15(4):267–71.  
91.  Thorner MO BGP. Recent advances in endocrinology and 
metabolism. 1st ed. JLH O, editor. Edinburg: Churchill 
Livingstone; 1978. 6–8. p.  
92.  Uilenbroek JT  van den LR. Effect of prolactin on follicular 
oestradiol production in the rat. J Endocrinol. 1984;102:245–50.  
 48 
 
93.  Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, 
Godwin AK, et al. Serum antimüllerian hormone in healthy 
premenopausal women. Fertil Steril. Elsevier Ltd; 
2011;95(8):2718–21.  
94.  Sahmay S, Usta T, Erel CT, Imamoglu M, Kücük M, Atakul N, 
et al. Is there any correlation between amh and obesity in 
premenopausal women. Arch Gynecol Obstet. 2012;286(3):661–
5.  
95.  Halawaty S, ElKattan E, Azab H, ElGhamry N A-IH. Effect of 
obesity on parameters of ovarian reserve in premenopausal 
women. JOGC J Obstet Gyn Can JOGC. 2010;32(7):687–90.  
96.  Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, 
Zylber-Haran E, et al. Serum anti-Mullerian hormone levels 
during controlled ovarian hyperstimulation in women with 
polycystic ovaries with and without hyperandrogenism. Hum 
Reprod. 2005;20(7):1814–9.  
97.  Skałba P, Cygal A, Madej P, Dbkowska-Huć A, Sikora J, 
Martirosian G, et al. Is the plasma anti-Müllerian hormone 
(AMH) level associated with body weight and metabolic, and 
hormonal disturbances in women with and without polycystic 
ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 
2011;158(2):254–9.  
98.  Buyuk E, Seifer DB, Illions E, Grazi R V., Lieman H. Elevated 
body mass index is associated with lower serum anti-mullerian 
hormone levels in infertile women with diminished ovarian 
reserve but not with normal ovarian reserve. Fertil Steril. 
Elsevier Ltd; 2011;95(7):2364–8.  
99.  Robker RL, Akison LK, Bennett BD, Thrupp PN, Chura LR, 
Russell DL, et al. Obese women exhibit differences in ovarian 
metabolites, hormones, and gene expression compared with 
moderate-weight women. J Clin Endocrinol Metab. 
 49 
 
2009;94(5):1533–40.  
100.  Robker RL, Wu LLY, Yang X. Inflammatory pathways linking 
obesity and ovarian dysfunction. J Reprod Immunol. Elsevier 
Ireland Ltd; 2011;88(2):142–8.  
 
 A 
 
Appendices 
Appendix 1: Data Collection Form 
Age  
Residence  
Occupation   
Level of Education   
Duration of Marriage   
Weight   
Height   
BMI   
Female Sex hormone  FSH LH PRL AMH 
    
Number of assisted ovulation trials. 
 
 
 
 
